Kringle Pharma,Inc.
Develops HGF-based regenerative medicines for rare and intractable diseases.
4884 | T
Overview
Corporate Details
- ISIN(s):
- JP3270790003
- LEI:
- Country:
- Japan
- Address:
- 茨木市彩都あさぎ七丁目７番１５号彩都バイオインキュベータ２０７号
- Sector:
- Manufacturing
Description
Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-24 07:01 |
有価証券届出書（新規公開時）
|
Japanese | 4.2 MB |
Automate Your Workflow. Get a real-time feed of all Kringle Pharma,Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kringle Pharma,Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kringle Pharma,Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
